Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Moderna Therapeutics (United States)
Abstract
MRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines. Pre-clinical and clinical studies have demonstrated that mRNA delivered intramuscularly (IM) with first-generation lipid nanoparticles (LNPs) generates robust immune responses. Despite progress made over the past several years, there remains significant opportunity for improvement, as the most advanced LNPs were designed for intravenous (IV) delivery of siRNA to the liver. Here, we screened a panel of proprietary biodegradable ionizable lipids for both expression…
Citation impact
- FWCI
- 25.38
- Percentile
- 100%
- References
- 36
Authors
19Topics & keywords
- Tolerability
- Immunogenicity
- Immune system
- Medicine
- Immunology
- Pharmacology
- Adverse effect
- Good health and well-being